Drug intelligence / Profile preview

DM 009

Development stage: Preclinical
Lead developer: Doma Pharmaceutical Technology
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Parenteral

Overview

DM 009 is a bispecific antibody drug conjugate being developed by Doma Bio for the treatment of solid tumours. It is classified as an antineoplastic agent and falls under the categories of bispecific antibodies, drug conjugates, and immunoconjugates. The precise mechanism of action has not been defined or disclosed publicly. As of March 2024, early research on this agent is ongoing in China[1].

Beyond the preview

Go deeper on DM 009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DM 009.

Explore the full profile